Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftriaxone Sodium

FDA-approved product (injectable, injection), marketed as Ceftriaxone, Ceftriaxone And Dextrose In Duplex Container, Ceftriaxone In Plastic Container and 3 more.

Registered studies
50+
Lab records
68
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceftriaxone Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Gonorrhea
  • Infection
  • Infectious meningitis
  • Otitis media
  • Pelvic Inflammatory Disease
  • Respiratory tract infectious disorder
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD04; WHO ATC J01DD54

Repurposing investigation

Ceftriaxone Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA82.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 8 of 8 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 26 of 56 lab records
Open Ceftriaxone Sodium in ChEMBL Registered studies below
Show the 68 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftriaxone Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients

    NCT07484633 · start 2026-04

    Registered record
    Registry ID
    NCT07484633
    Conditions
    Infection; Sepsis; NICU; PICU; Beta Lactams
    Interventions
    Extended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime; Extended infusion time of the following beta-lactam: ceftriaxone; Short-term infusion time of the following beta-lactam: piperacillin/tazobactam; Short-term infusion time of the following beta-lactam: cefepime; Short-term infusion time of the following beta-lactam: ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Sepsis; NICU; PICU +1 more
    InterventionExtended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime +4 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting

  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes

    NCT07148622 · start 2024-10-01

    Registered record
    Registry ID
    NCT07148622
    Conditions
    Preterm Premature Rupture of Membranes (PPROM); Prophylaxis; Perinatal Outcomes
    Interventions
    Antibiotic regimen 1: sulbactam + ampicillin + azithromycin; Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2025-08-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Premature Rupture of Membranes (PPROM); Prophylaxis; Perinatal Outcomes
    InterventionAntibiotic regimen 1: sulbactam + ampicillin + azithromycin; Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin
    PhaseNot applicable
    Registry statusCompleted

  • Study of the Pharmacokinetics of Ceftriaxone

    NCT07169097 · start 2024-09-30

    Registered record
    Registry ID
    NCT07169097
    Conditions
    Urinary Infections
    Interventions
    free ceftriaxone concentration dosage
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2024-09-30
    Completion
    2025-12-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Infections
    Interventionfree ceftriaxone concentration dosage
    PhaseNot recorded
    Registry statusTerminated

  • Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis

    NCT05761405 · start 2024-01-16

    Registered record
    Registry ID
    NCT05761405
    Conditions
    Urinary Tract Infections; Urological System Complication of Procedure
    Interventions
    mannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2024-01-16
    Completion
    2026-04-15
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Urological System Complication of Procedure
    Interventionmannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    PhaseEarly phase 1
    Registry statusUnknown

  • Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study

    NCT05971550 · start 2023-09

    Registered record
    Registry ID
    NCT05971550
    Conditions
    Neisseria Gonorrhoeae Infection; Asymptomatic Pharyngeal Carriage
    Interventions
    Absence of antibiotic treatment; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-09
    Completion
    2025-12
    Enrolment
    254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeisseria Gonorrhoeae Infection; Asymptomatic Pharyngeal Carriage
    InterventionAbsence of antibiotic treatment; Ceftriaxone
    PhasePhase 3
    Registry statusUnknown

  • Comparison Between 6Fr Vs 4Fr Double J Stent

    NCT05725226 · start 2023-04-07

    Registered record
    Registry ID
    NCT05725226
    Conditions
    Renal Stone; Ureter Stone
    Interventions
    Double J Stent 6Fr x 26cms; Double J Stent 4Fr x26cms
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-07
    Completion
    2023-12-21
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Stone; Ureter Stone
    InterventionDouble J Stent 6Fr x 26cms; Double J Stent 4Fr x26cms
    PhaseNot applicable
    Registry statusCompleted

  • Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline

    NCT05980871 · start 2023-03-10

    Registered record
    Registry ID
    NCT05980871
    Conditions
    Early Syphilis
    Interventions
    Doxycycline; Ceftriaxone; benzathine penicillin G
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-03-10
    Completion
    2025-07-25
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Syphilis
    InterventionDoxycycline; Ceftriaxone; benzathine penicillin G
    PhasePhase 4
    Registry statusTerminated

  • Propranolol on Post Stroke Immune Status and Infection

    NCT05375240 · start 2022-06

    Registered record
    Registry ID
    NCT05375240
    Conditions
    Stroke; Cerebrovascular Disorders; Ischemic Stroke; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Cardiovascular Diseases; Propranolol; Beta Blocker; Molecular Mechanisms of Pharmacological Action; Immunologic Factors; Physiological Effects of Drugs
    Interventions
    Propranolol; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-06
    Completion
    2024-06
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Cerebrovascular Disorders; Ischemic Stroke; Brain Diseases +8 more
    InterventionPropranolol; Ceftriaxone
    PhasePhase 2
    Registry statusUnknown

  • Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

    NCT05294588 · start 2022-04-18

    Registered record
    Registry ID
    NCT05294588
    Conditions
    Gonorrhea Male
    Interventions
    Cefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090; Meningococcal Group B Vaccine; Influenza Vaccine; Tetanus-diptheria Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-04-18
    Completion
    2026-02-05
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea Male
    InterventionCefixime; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 +3 more
    PhasePhase 2
    Registry statusCompleted

  • Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea

    NCT05027516 · start 2022-01-17

    Registered record
    Registry ID
    NCT05027516
    Conditions
    Neisseria Gonorrhoeae
    Interventions
    Rocephin; Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-17
    Completion
    2022-05-09
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeisseria Gonorrhoeae
    InterventionRocephin; Azithromycin
    PhasePhase 4
    Registry statusCompleted

  • PROPER Trial of Pain and Inflammation After Knee Arthroscopy

    NCT05149287 · start 2021-12-28

    Registered record
    Registry ID
    NCT05149287
    Conditions
    Meniscus Tear; Meniscus Lesion; Cartilage Injury
    Interventions
    Ceftriaxone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-12-28
    Completion
    2022-04-29
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeniscus Tear; Meniscus Lesion; Cartilage Injury
    InterventionCeftriaxone; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery

    NCT05398081 · start 2021-12-01

    Registered record
    Registry ID
    NCT05398081
    Conditions
    Surgical Site Infection; Antibiotics Prophylaxis
    Interventions
    Cefuroxime (Zinnat®); Ceftriaxone (Rocephin®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2022-03-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection; Antibiotics Prophylaxis
    InterventionCefuroxime (Zinnat®); Ceftriaxone (Rocephin®)
    PhasePhase 2
    Registry statusCompleted

  • Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

    NCT04999592 · start 2021-08-20

    Registered record
    Registry ID
    NCT04999592
    Conditions
    Out-Of-Hospital Cardiac Arrest; Pneumonia
    Interventions
    Standard of care without prophylaxis; Antibiotic prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-08-20
    Completion
    2024-11-01
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOut-Of-Hospital Cardiac Arrest; Pneumonia
    InterventionStandard of care without prophylaxis; Antibiotic prophylaxis
    PhasePhase 2
    Registry statusTerminated